Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...

Sales of Wegovy, a prescription weight loss injection, surged to 19.9 billion Danish kroner (£2.2 billion) in the fourth ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price ...

The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face ...

As we mentioned on Tuesday, the majority of companies on the S&P 500 that have reported earnings, have beaten estimates, and ...

Find insight on Novo Nordisk, GSK and more in the latest Market Talks covering Health Care.

Novo Nordisk expects sales growth to slow this year as capacity constraints, intensifying competition and pricing pressure drag on sales of its blockbuster weight-loss and diabetes drugs. The Danish ...

Ozempic, which accounts for 41% of the company's sales, is an injectable anti-diabetic treatment that became wildly popular ...

LONDON/COPENHAGEN (Reuters) -Wegovy maker Novo Nordisk on Wednesday forecast slower sales growth for 2025 than 2024, a blow ...

Ozempic is traditionally used as a treatment for type 2 diabetes (T2DM) to help patients manage blood sugar levels. However, ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.